Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
31 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Vernalis plc - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Vernalis plc - Product Pipeline Review - 2014', provides an overview of the Vernalis plc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Vernalis plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Vernalis plc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Vernalis plc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Vernalis plc's pipeline products Reasons to buy - Evaluate Vernalis plc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Vernalis plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Vernalis plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Vernalis plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vernalis plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Vernalis plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Vernalis plc Snapshot 5 Vernalis plc Overview 5 Key Information 5 Key Facts 5 Vernalis plc - Research and Development Overview 6 Key Therapeutic Areas 6 Vernalis plc - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Vernalis plc - Pipeline Products Glance 14 Vernalis plc - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Vernalis plc - Early Stage Pipeline Products 15 Discovery Products/Combination Treatment Modalities 15 Vernalis plc - Drug Profiles 16 V-158866 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 V-81444 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Small Molecule to Inhibit Chk1 for Oncology 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Vernalis plc - Pipeline Analysis 19 Vernalis plc - Pipeline Products by Target 19 Vernalis plc - Pipeline Products by Route of Administration 20 Vernalis plc - Pipeline Products by Molecule Type 21 Vernalis plc - Pipeline Products by Mechanism of Action 22 Vernalis plc - Recent Pipeline Updates 23 Vernalis plc - Dormant Projects 25 Vernalis plc - Discontinued Pipeline Products 26 Discontinued Pipeline Product Profiles 26 alphadolone 26 BB-2827 26 indantadol 26 marimastat 26 solimastat 27 V-1003 27 V-10153 27 V-24343 27 VML-670 27 Vernalis plc - Company Statement 28 Vernalis plc - Locations And Subsidiaries 29 Head Office 29 Other Locations & Subsidiaries 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 31 Disclaimer 31
List of Tables Vernalis plc, Key Information 5 Vernalis plc, Key Facts 5 Vernalis plc - Pipeline by Indication, 2014 7 Vernalis plc - Pipeline by Stage of Development, 2014 8 Vernalis plc - Monotherapy Products in Pipeline, 2014 9 Vernalis plc - Partnered Products in Pipeline, 2014 10 Vernalis plc - Partnered Products/ Combination Treatment Modalities, 2014 11 Vernalis plc - Out-Licensed Products in Pipeline, 2014 12 Vernalis plc - Out-Licensed Products/ Combination Treatment Modalities, 2014 13 Vernalis plc - Phase II, 2014 14 Vernalis plc - Discovery, 2014 15 Vernalis plc - Pipeline by Target, 2014 19 Vernalis plc - Pipeline by Route of Administration, 2014 20 Vernalis plc - Pipeline by Molecule Type, 2014 21 Vernalis plc - Pipeline Products by Mechanism of Action, 2014 22 Vernalis plc - Recent Pipeline Updates, 2014 23 Vernalis plc - Dormant Developmental Projects,2014 25 Vernalis plc - Discontinued Pipeline Products, 2014 26 Vernalis plc, Subsidiaries 29
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.